Cutaneous drug reaction secondary to antitubercular regimen: A case report from Nepal.

Autor:	Bhattarai HB; Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal., Yadav J; Institute of Medicine, Tribhuvan University, Kathmandu, Nepal., Sapkota S; Institute of Medicine, Tribhuvan University, Kathmandu, Nepal., Adhikari A; Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal., Bhattarai M; Institute of Medicine, Tribhuvan University, Kathmandu, Nepal., Singh I; Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal., Shrestha S; Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal., Kc J; Nobel Medical College Teaching Hospital, Biratnagar, Nepal., Karki P; Green Pastures Hospital, Pokhara, Nepal., Basnet B; B.P. Koirala Institute of Health Science, Dharan, Nepal.
Jazyk:	angličtina
Zdroj:	SAGE open medical case reports [SAGE Open Med Case Rep] 2023 Nov 09; Vol. 11, pp. 2050313X231210390. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
DOI:	10.1177/2050313X231210390
Abstrakt:	Cutaneous adverse drug reactions are known side effects of first-line antitubercular therapy, which ranges from mild pruritus to life-threatening toxic epidermal necrolysis. Severe cutaneous adverse drug reactions can lead to antitubercular therapy discontinuation and further complicates tuberculosis treatment. Here we present the case of a 49-year-old obese male who developed a generalized maculopapular rash within 24 hours of initiation of therapy followed by bullae over palms in 3 days. Antitubercular therapy was immediately discontinued, and he was managed with antihistamines, intravenous fluid, and electrolyte supplementation. He was discharged on antihistamines, a short course of systemic steroids, moxifloxacin, and bedaquiline (second-line antitubercular therapy (ATT)). Proper guidelines about rechallenge therapy will enormously aid in managing cutaneous adverse drug reactions, and efficient treatment of tuberculosis in these patients, and ceasing its progression to multisystemic complications. This article aims to discuss the presentation and management of cutaneous adverse drug reactions in the setting of Nepal. Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu